Maciej Wieczorek in Poland Healthcare&Life Sciences Review – an interview

President of the Company, Maciej Wieczorek, about Celon’s business plans and the perspectives of development of the Polish biotech industry in an interview given to Poland Healthcare & Life Sciences Review Pharmaceutical Executive Magazine. We encourage you to read the interview.

Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants

Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: Participants receivedRead more »

Celon Pharma S.A. at EIT Health Matchmaking

250 participants: scientists and entrepreneurs, 3 days of debates and meetings on the most important challenges in the area of health and innovation in Europe, including representatives of Celon Pharma. The biggest meeting of this year was aimed at developing the main pillars of the EIT Health agenda in 2018/2019. Jerzy Pieczykolan, PhD, Head ofRead more »

Maciej Wieczorek, at the Impact CEE conference, talking about financing the Polish biotechnology industry and its future

Maciej Wieczorek, CEO was a guest of the Impact CEE conference . A series of such meetings is attended by representatives of national research institutes, Polish and international companies, the public administration and representatives of start-ups. The subject of the first debate was the biotech industry, it took place on 19 February 20118 at theRead more »

Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials

Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »